193 related articles for article (PubMed ID: 37823831)
1. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.
Das A; Fernandez NR; Levine A; Bianchi V; Stengs LK; Chung J; Negm L; Dimayacyac JR; Chang Y; Nobre L; Ercan AB; Sanchez-Ramirez S; Sudhaman S; Edwards M; Larouche V; Samuel D; Van Damme A; Gass D; Ziegler DS; Bielack SS; Koschmann C; Zelcer S; Yalon-Oren M; Campino GA; Sarosiek T; Nichols KE; Loret De Mola R; Bielamowicz K; Sabel M; Frojd CA; Wood MD; Glover JM; Lee YY; Vanan M; Adamski JK; Perreault S; Chamdine O; Hjort MA; Zapotocky M; Carceller F; Wright E; Fedorakova I; Lossos A; Tanaka R; Osborn M; Blumenthal DT; Aronson M; Bartels U; Huang A; Ramaswamy V; Malkin D; Shlien A; Villani A; Dirks PB; Pugh TJ; Getz G; Maruvka YE; Tsang DS; Ertl-Wagner B; Hawkins C; Bouffet E; Morgenstern DA; Tabori U
Cancer Discov; 2024 Feb; 14(2):258-273. PubMed ID: 37823831
[TBL] [Abstract][Full Text] [Related]
2. Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns.
Dodgshun AJ; Fukuoka K; Edwards M; Bianchi VJ; Das A; Sexton-Oates A; Larouche V; Vanan MI; Lindhorst S; Yalon M; Mason G; Crooks B; Constantini S; Massimino M; Chiaravalli S; Ramdas J; Mason W; Ashraf S; Farah R; Van Damme A; Opocher E; Hamid SA; Ziegler DS; Samuel D; Cole KA; Tomboc P; Stearns D; Thomas GA; Lossos A; Sullivan M; Hansford JR; Mackay A; Jones C; Jones DTW; Ramaswamy V; Hawkins C; Bouffet E; Tabori U
Acta Neuropathol; 2020 Nov; 140(5):765-776. PubMed ID: 32895736
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.
Campbell BB; Galati MA; Stone SC; Riemenschneider AN; Edwards M; Sudhaman S; Siddaway R; Komosa M; Nunes NM; Nobre L; Morrissy AS; Zatzman M; Zapotocky M; Joksimovic L; Kalimuthu SN; Samuel D; Mason G; Bouffet E; Morgenstern DA; Aronson M; Durno C; Malkin D; Maris JM; Taylor MD; Shlien A; Pugh TJ; Ohashi PS; Hawkins CE; Tabori U
Cancer Discov; 2021 Jun; 11(6):1454-1467. PubMed ID: 33563663
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.
Das A; Sudhaman S; Morgenstern D; Coblentz A; Chung J; Stone SC; Alsafwani N; Liu ZA; Karsaneh OAA; Soleimani S; Ladany H; Chen D; Zatzman M; Cabric V; Nobre L; Bianchi V; Edwards M; Sambira Nahum LC; Ercan AB; Nabbi A; Constantini S; Dvir R; Yalon-Oren M; Campino GA; Caspi S; Larouche V; Reddy A; Osborn M; Mason G; Lindhorst S; Bronsema A; Magimairajan V; Opocher E; De Mola RL; Sabel M; Frojd C; Sumerauer D; Samuel D; Cole K; Chiaravalli S; Massimino M; Tomboc P; Ziegler DS; George B; Van Damme A; Hijiya N; Gass D; McGee RB; Mordechai O; Bowers DC; Laetsch TW; Lossos A; Blumenthal DT; Sarosiek T; Yen LY; Knipstein J; Bendel A; Hoffman LM; Luna-Fineman S; Zimmermann S; Scheers I; Nichols KE; Zapotocky M; Hansford JR; Maris JM; Dirks P; Taylor MD; Kulkarni AV; Shroff M; Tsang DS; Villani A; Xu W; Aronson M; Durno C; Shlien A; Malkin D; Getz G; Maruvka YE; Ohashi PS; Hawkins C; Pugh TJ; Bouffet E; Tabori U
Nat Med; 2022 Jan; 28(1):125-135. PubMed ID: 34992263
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
9. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
10. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
11. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
[TBL] [Abstract][Full Text] [Related]
12. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
13. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
Bouffet E; Larouche V; Campbell BB; Merico D; de Borja R; Aronson M; Durno C; Krueger J; Cabric V; Ramaswamy V; Zhukova N; Mason G; Farah R; Afzal S; Yalon M; Rechavi G; Magimairajan V; Walsh MF; Constantini S; Dvir R; Elhasid R; Reddy A; Osborn M; Sullivan M; Hansford J; Dodgshun A; Klauber-Demore N; Peterson L; Patel S; Lindhorst S; Atkinson J; Cohen Z; Laframboise R; Dirks P; Taylor M; Malkin D; Albrecht S; Dudley RW; Jabado N; Hawkins CE; Shlien A; Tabori U
J Clin Oncol; 2016 Jul; 34(19):2206-11. PubMed ID: 27001570
[TBL] [Abstract][Full Text] [Related]
16. Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group.
Müller K; Scheithauer H; Pietschmann S; Hoffmann M; Rössler J; Graf N; Baumert BG; Christiansen H; Kortmann RD; Kramm CM; von Bueren AO
Radiat Oncol; 2014 Aug; 9():177. PubMed ID: 25112658
[TBL] [Abstract][Full Text] [Related]
17. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
[TBL] [Abstract][Full Text] [Related]
19. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
20. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
